Success Metrics

Clinical Success Rate
66.7%

Based on 6 completed trials

Completion Rate
67%(6/9)
Active Trials
2(13%)
Results Posted
0%(0 trials)
Terminated
3(19%)

Phase Distribution

Ph phase_1
1
6%
Ph not_applicable
6
38%
Ph phase_2
3
19%
Ph phase_3
3
19%

Phase Distribution

1

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
1(7.7%)
Phase 2Efficacy & side effects
3(23.1%)
Phase 3Large-scale testing
3(23.1%)
N/ANon-phased studies
6(46.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

54.5%

6 of 11 finished

Non-Completion Rate

45.5%

5 ended early

Currently Active

2

trials recruiting

Total Trials

16

all time

Status Distribution
Active(3)
Completed(6)
Terminated(5)
Other(2)

Detailed Status

Completed6
Terminated3
Recruiting2
Withdrawn2
Suspended1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
2
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (7.7%)
Phase 23 (23.1%)
Phase 33 (23.1%)
N/A6 (46.2%)

Trials by Status

suspended16%
unknown16%
recruiting213%
withdrawn213%
completed638%
enrolling_by_invitation16%
terminated319%

Recent Activity

2 active trials
Showing 5 of 16
suspended

Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient

NCT05422105
recruitingphase_3

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

NCT06122584
withdrawnphase_1

Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC

NCT06881823
recruitingphase_3

18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028

NCT05520255
completedphase_3

Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer

NCT04742361
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT05422105

Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient

Suspended
NCT06122584Phase 3

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

Recruiting
NCT06881823Phase 1

Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC

Withdrawn
NCT05520255Phase 3

18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028

Recruiting
NCT04742361Phase 3

Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer

Completed
NCT05534594Not Applicable

Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer

Completed
NCT05712174Phase 2

A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer

Terminated
NCT05815316Phase 2

18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer

Withdrawn
NCT05123300Not Applicable

PRISMA-PET - Primary Staging of Prostate Cancer With PSMA

Terminated
NCT06723665Not Applicable

The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients

Enrolling By Invitation
NCT05709535

PSMA-PET/CT Registry

Terminated
NCT05079828Not Applicable

Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007

Completed
NCT04733768Phase 2

18F-PSMA-1007 PET/CT Imaging in Patients with Biochemically Recurrent or High-risk Prostate Cancer

Completed
NCT04986280

Diagnostic Accuracy and Performance of 18F-PSMA-1007

Completed
NCT05448404Not Applicable

A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma

Unknown
NCT03187990Not Applicable

Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16